NCT00547144View on ClinicalTrials.gov

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

1000 mg/m2 intravenoulsy once a week according to protocol schedule

PROCEDURE

Dendritic Cell Immunotherapy

The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

George Albert Fisher

OTHER

NCT00547144 - Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter